BGC-0228

N/A

Report date: 2022/04/19 14:29:17
NME

Base Information

Drug NameBGC-0228
Drug Alias NameBGC-0228
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionCD44 antigen inhibitors
TargetsCD44 antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBrightgene Bio-Medical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBrightgene Bio-Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A